Exicure Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Paul Kang

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

CEO

Paul Kang (61 yo)

less than a year

Tenure

Mr. Paul Kang is Director of Exicure, Inc. from February 24, 2023 and serves as its Chief Executive Officer since August 21, 2023. He is associated with CBI USA Inc. Mr. Kang began his 35-year investment a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Kang	CEO & Director	less than a year	no data	no data
Jiyoung Hwang	CFO & Director	less than a year	no data	no data
Joshua Miller	Chief Accounting Officer	less than a year	no data	0.011% $ 463.5
Bart Anderson	Senior Director of R&D	no data	no data	no data

0.8yrs

Average Tenure

47yo

Average Age

Experienced Management: XCUR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Kang	CEO & Director	1.3yrs	no data	no data
Jiyoung Hwang	CFO & Director	1.1yrs	no data	no data
Michael Hodges	Member of Advisory Board	no data	no data	no data
Amy Paller	Member of Advisory Board	no data	no data	no data
Henry Paulson	Member of Advisory Board	4.4yrs	no data	no data
Hojoon Lee	Director	less than a year	no data	no data
Hyuk Ko	Director	less than a year	no data	no data
Dongho Lee	Director	less than a year	no data	no data
Minhee Eom	Director	less than a year	no data	no data

0.8yrs

Average Tenure

49yo

Average Age

Experienced Board: XCUR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Exicure Management

Management criteria checks 0/4

Key information

Recent management updates

No independent directors

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Recent updates

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Consensus revenue estimates increase to US$8.91m

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election

Exicure Announces Appointments of Board of Directors

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

New 90-day high: US$2.80

Exicure Appoints James Sulat to Board of Directors

A Look At Exicure's (NASDAQ:XCUR) Share Price Returns

Exicure, Inc. Announces That the U.S. Food and Drug Administration (Fda) Has Granted Fast Track Designations for Its Clinical Product Candidate

New 90-day high: US$2.30

Exicure, Inc. Announces Executive Changes

Exicure announces issuance of two new U.S. patents, and new patent allowance

New 90-day high: US$1.99

How Much Of Exicure, Inc. (NASDAQ:XCUR) Do Institutions Own?

New 90-day low: US$1.47

Analysts update estimates

Exicure (XCUR) Investor Presentation - Slideshow